Mass. General Team Develops Iphone App to Screen for Postpartum Depression

Free, first-of-its-kind tool aimed at refining how women are screened for postpartum depression

pancreatic cancer, pancreatic cancer, celiac disease, cancer immunotherapy, pediatric cancer cells, celiac disease, neurodegenerative disorders, CRISPR, dementia, mitochondria, brain tumors, genetic disorder, stem cell, chronic health, neurological disorder, sleep duration, heart failure, acute myeloid leukemia, Tourette's syndrome, acute myeloid leukemia, Insomnia, breast cancer, brain cells, HPV infection, schizophrenia, opioid overdose, cardiovascular health, metastatic breast cancer, depression, ovarian cancer, HIV protein function, menopause, Down syndrome, Alzheimer's disease, melanoma treatment, muscular dystrophy therapies, Ezogabine treatment, hereditary angioedema, hypertension, melanoma, cervical cancer, depression, neurodegenerative diseases, anesthetic drug ketamine, Olfactory cells, Dopamine Receptors, Muscular Dystrophy, Alzheimer’s disease, Alzheimer's, brain tumors, amygdala, freezing point, brain tumors, Rett Syndrome, cardiovascular death, Chronic viral infection, folic acid, diabetes, brain function, post-traumatic stress disorder, X chromosome, Maternal Fatty Acid, chronic sciatica, preemie blindness, gliomas, breast cancer, Combination immunotherapy, prostate cancer, acute heart failure, Metastatic lymph nodes, obesity, spontaneous coronary artery dissection, movement disorder, Safe-sleep, electronic cigarettes, prostate cancer, radiation therapy, neonatal disease, chemotherapy, tumor cells, X-linked disorders, autoimmune disease, neurological disorder, transplantation, tumor cells, Pulmonary Fibrosis, Nerve-damage Disorder, Mature B Lymphocytes, Alzheimer's Disease, hepatitis c infection, depression, penicillin, Leukemia, Anti-Angiogenesis, diabetes, conversion disorder, lymphoma, kidney disease, cancer, diabetes, autism, Tourette syndrome

Researchers at Massachusetts General Hospital’s (MGH) Ammon-Pinizzotto Center for Women’s Mental Health have developed the MGH Perinatal Depression Scale (MGHPDS), a free iPhone application designed to refine how women around the world are screened for postpartum depression (PPD). The app includes questionnaires about mood, anxiety, sleep and stress at important time periods during and after pregnancy. The questionnaires will identify which specific symptoms are most critical in the diagnosis of PPD in women ages 18-45 who are pregnant or up to 12 weeks postpartum.

“The rapid growth of mHealth in psychiatry has led to the development of a variety of web-driven screening tools for many mental health issues, yet to date there has been little attention to the use of technology to better diagnose and treat PPD,” says Lee S. Cohen, MD, director of the Ammon-Pinizzotto Center and professor of Psychiatry at Harvard Medical School. “Further complicating matters is the wide prevalence of false positives, which occur approximately 25 percent of the time when using currently available scales.”

PPD is the most common psychiatric complication women experience following the birth of a child. Although 10 to 15 percent of women may suffer from PPD, it is frequently undiagnosed and untreated, which can lead to lasting negative effects for both the mother and her child. The MGHPDS app blends together digital versions of perinatal depression screening tools such as the Edinburgh Postpartum Depression Scale, a 10-question self-rating scale which is the most common tool for identifying women at risk for PPD, with other instruments that measure symptoms associated with perinatal psychiatric illness – such as sleep disturbance, anxiety and perceived stress.

“Those who download the app and complete the included questionnaires may also consent to share their scores with researchers within our center here at MGH, further assisting in the development of an even shorter scale with greater specificity than what is currently available,” says Cohen. “It is our hope that –  as screening for PPD becomes increasingly common across the U.S. and globally – easy-to-use tools like the MGHPDS, which can be readily used on smartphones and other digital devices, will lead to more accurate screening of perinatal mood and anxiety disorders and to improved clinical outcomes for patients.”

The app is free and can be downloaded via the App Store. An Android version will launch later this fall, with version 2.0 of the app launching in the second half of 2018.

The app is latest development from the Ammon-Pinizzotto Center for Women’s Mental Health, which focuses on a range of psychiatric disorders and research – including pregnancy and postpartum psychiatric disorders, peri- and post-menopausal depression, and premenstrual dysphoric disorder. The mission of the center is to provide state-of-the-art evaluation and ongoing care for women who suffer from a spectrum of psychiatric disorders and to improve the lives of patients and their families. Clinical care at the center is complemented by research across a range of areas, the goal of which is to address critical unanswered questions that can inform clinical care and to disseminate important research findings that emerge across the field of women’s mental health.

Source : Massachusetts General Hospital